Sanofi is making successful strides to restock its pipeline and shore up revenue streams amid the looming patent expiry of its best-selling asset, Dupixent (dupilumab).
In FY2025, the French pharmaceutical company achieved net sales of €43.6bn ($51.9bn) – up 9.9% in constant exchange rates (CER) from FY2024. Earnings per share (EPS) stood at €7.83 for FY2025, 1% ahead of consensus, as per Citi analysts.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
This overall growth was primarily driven by a 25.2% increase, at CER, in sales of type 2 inflammation-targeting biologic, Dupixent, which reached a global total of €15.7bn ($18.72bn) across the year. This exceeded the 23.1% growth rate and €13bn sales achieved in FY2024 for the drug that Sanofi co-markets with Regeneron.
Outside of immunology, Sanofi’s multiple myeloma therapy, Sarclisa (isatuximab) was another asset that displayed strong sales growth, with the therapy generating 28.5% more in sales YoY at a value of €588m ($700.1m).
Within its vaccine portfolio, sales outside of the US facilitated the continued growth of respiratory syncytial virus (RSV) jab Beyfortus (nirsevimab), which pulled in €1.8bn – marking a 9.5% overall increase from 2024. The strong YoY sales increase observed across Europe (38.1%) and the rest of the world (165.8%) offset the steep 27.8% decline in vaccine sales across the US, as the Trump administration looks to alter vaccine policy.
In Sanofi’s rare disease portfolio, the company’s haemophilia A therapy Altuviiio (efanesoctocog alfa) experienced a 77.6% sales boost – reaching blockbuster status by bringing in a total of €1.2bn over the year.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn a company presentation, the pharma company’s CEO, Paul Hudson noted that 12 of its newer launches – including Sarclisa, Beyfortus and Altuviio – grew 34% in 2025, which could successfully prepare the company for the upcoming patent cliff, which GlobalData estimates will trigger a $230bn value decline in the US market between 2025 and 2030.
R&D and AI drive Sanofi’s goals
As Sanofi looks to maintain its growth, Hudson noted that the company will home in on its artificial intelligence (AI) and R&D-driven strategy.
To achieve this, the company is running several mid-to-late-stage development projects across immunology, rare disease, oncology, neurology and vaccines.
Sanofi is expecting multiple Phase III readouts across 2026 – including results from the late-stage STYLE 1 (NCT06687967) study on Dupixent in Lichen Simplex Chronicus (LSC) in H2 2026.
The French pharma company is also awaiting results from two Phase III studies on its glucosylceramide synthase pill for lysosomal storage disorders, venglustat. The PERIDOT study (NCT05206773) is currently evaluating the therapy in Fabry disease, while the LEAP2MONO trial (NCT05222906) is exploring the drug’s potential in Gaucher Disease Type 3 (GD3). Sanofi expects both trials to read out in H1 2026.
